Skip to content

Application and promotion of GnRHa combined with Sanjie Zhentong capsule in the long-term management of endometriosis

Application and promotion of GnRHa combined with Sanjie Zhentong capsule in the long-term management of endometriosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900025324
Enrollment
Unknown
Registered
2019-11-04
Start date
2020-12-21
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Women with stage III to IV of endometriosis confirmed by operation and received the conservative surgery; (2) women who were within 18-45 years old, (3) Women should be able to express their complaints and answers to symptoms in well mental and physical state. (4) No birth plan within one year; (5) Informed consent was signed;

Exclusion criteria

Exclusion criteria: (1) Patients who suffer gynecologic malignant tumor, genital tubercle, or those endometriosis patients who had underwent total hysterectomy with bilateral salpingo-oophorectomy; (2) Patients who suffer together with other internal diseases, like cardiovascular, hepatic, renal, or hematopoietic disease; (3) Combined with other gynecological endocrine diseases, such as PCOS; (4) Pregnancies or lactation; or patients who are allergic to the experimental drug; or those who have participated in other clinical trials; (5) Hb < 80g/L; (6) Patients with the family history of thrombosis or thrombotic disease. (7) Women with stage I to II of endometriosis confirmed by operation. (8) Patients with some other conditions that researchers considered unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
the MOS item short from health survey, SF-36;Recurrence Rate;pelvic lesion;VAS score;

Secondary

MeasureTime frame
pregnancy rate;Ovarian Function;CA125;

Countries

China

Contacts

Public ContactCongjian Xu

Obstetrics and Gynecology Hospital of Fudan University

xucj@hotmail.com+86 13651796353

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026